Navigation Links
Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
Date:6/17/2011

erience.

About the Avanafil Phase 3 ProgramThe avanafil phase 3 program consists of three studies: TA-301 (REVIVE), TA-302 (REVIVE-Diabetes), and TA-303 (REVIVE-RP) and a 52-week, open-label, long-term safety study (TA-314). TA-301, TA-302 and TA-303 were all randomized, double-blind, placebo-controlled phase 3 studies of avanafil in 646, 390, and 298 men respectively with a history of ED for at least six months.  Each of the pivotal trials had a similar trial design with patients undergoing a four-week, non-treatment run-in period followed by 12 weeks of treatment. Primary endpoints of the studies were improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the EF domain score of the International Index of Erectile Function (IIEF). In all three studies, all doses of avanafil tested met the primary endpoints, with successful intercourse achieved by some subjects in 15 minutes or less after administration.  

TA-314 evaluated avanafil for up to 52-weeks in 712 men, 486 with a history of ED and 226 diabetic men with ED across 40 centers throughout the U.S.  Patients completing REVIVE (TA-301) or REVIVE-Diabetes (TA-302) were eligible for rollover into TA-314.  The study met all primary endpoints by demonstrating sustained improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP 2 and SEP 3) and improvements in the International Index of Erectile Function (IIEF).  The study also indicated a favorable side effect profile and successful intercourse (as measured by SEP 3) in as little as 15 minutes and beyond six hours after dosing, without any restrictions on food or alcohol intake.

VIVUS held a pre-NDA meeting with the FDA to confirm that the pre-clinical and clinical requirements necessary for the filing of an NDA have been met. In total, the phase 3 avanafil clinical program enrolled approximately 1,350 subjects. VIVUS
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurelis Announces Positive Results from Phase 1 Pharmacokinetic Study of NRL-01 (intranasal diazepam)
2. Dong-A PharmTech Co., Ltd. and Dr. Falk Pharma GmbH Announce Positive Data in Portal Hypertension With Udenafil
3. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
4. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
5. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
6. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
7. KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
8. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
9. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
10. Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Reportlinker Adds Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Oct. 2, 2014   West Pharmaceutical Services, Inc. ... in innovative solutions for injectable drug administration, announced today ... include a new site in Waterford, Ireland ... for insulin injector cartridges and other high-value packaging components, ... biotech customers. Once operational, this new site could bring ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014  Abaxis, Inc. ... manufacturing point-of-care instruments and consumables for the medical, research, ... to the veterinary and research markets in ... entered into a definitive distribution agreement with Patterson Veterinary ... and promote the full line of Abaxis veterinary products ...
(Date:10/1/2014)... JUPITER, Fla. , Oct. 1, 2014 /PRNewswire/ ... biotechnology company with patented and proprietary technology used ... for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial ... $500,000 licensing payment from Abengoa Bioenergy for commercial ... for converting biomass into ethanol, developed under Abengoa,s ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... 9, 2007 -,GlaxoSmithKline (LSE and NYSE:GSK) and ... 767905/014 and,provided an update on the clinical ... Phase 3, double blind, placebo-controlled (12,month) study, ... and,tolerability of alvimopan 0.5 mg twice daily ...
... Educate on Good,Diabetes Management and How to Reduce ... 10, 2007 /PRNewswire/ -- A first-of-its-kind,report looking at ... shows that an estimated three out of five ... least one of the other,serious health problems commonly ...
Cached Medicine Technology:GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7
(Date:10/2/2014)... October 02, 2014 Recently, BambooIndustry.com, a ... its new collection of bamboo floors . What’s ... a lot of its products at the moment. According ... up to 26 percent off. The promotion will be ... floors ( http://www.bambooindustry.com ) are all made by qualified ...
(Date:10/2/2014)... BamboofloorChina.com is a distinguished bamboo product ... great appreciation from the global customers in the past ... make more excellent items. All its online workers are ... clients. , The company has recently added a ... website. Furthermore, the company’s marketing specialist has announced that ...
(Date:10/2/2014)... with autism are more sedentary than those without the ... a small study suggests. Researchers tested the fitness ... and some without. Children with autism averaged 50 fewer ... more minutes each day sitting than those without autism. ... strength, but had similar body-mass index (a measurement of ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... Columbia now have a total of 500 confirmed cases of ... children since the summer, U.S. health officials reported Wednesday. ... recent weeks, but it,s not clear what role -- if ... Health officials are also trying to determine if the ...
(Date:10/1/2014)... research study published today in the Journal of ... older than 50 years with moderate or severe chronic ... Researchers from the University of Melbourne randomly assigned 282 ... to no acupuncture or sham or pretend laser treatment. ... participants and acupuncturists blinded to laser and sham (inactive) ...
Breaking Medicine News(10 mins):Health News:BambooIndustry.com: Great Bamboo Floors At Discounted Rates 2Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2
... spending on medical research in Europe should be doubled ... welfare for Europes citizens and to nurture a thriving ... between European institutions in medical research and improved career ... the main recommendations of the European Medical Research Councils ...
... VICTORVILLE, Calif., Feb. 5 Dr. Richard Merkin ... Senior,Valentine,s Day Luncheon. They will host this special luncheon ... Victorville Senior Hall., The event is open to ... down,meal from Carino,s Italian Grill and entertainment by the ...
... more likely than nonsmokers to report lack of restful slumber, ... are four times more likely to feel tired when they ... than nonsmokers do, a new study finds. , This may ... contribute to sleep disturbances, suggest the study authors, whose report ...
... finding turned out to be a clue leading researchers ... to propose a new treatment approach for Niemann-Pick disease, ... the genetic defect in Niemann-Pick disease, the researchers suggest ... through the cell,s quality control machinery. And they believe ...
... Agency has finalised an agreement with an ESA-led ... which contributes to the premature deaths of hundreds ... agreement, the European Environment Agency (EEA) will use ... with surface measurements from 29 European countries to ...
... 5 Keystone Human Services (KHS),is pleased ... Inc., a privately,owned, Pennsylvania based for-profit agency ... autism for 35 years. Impact,Systems, Inc., serving ... will become an important component of,Keystone,s regional ...
Cached Medicine News:Health News:Collaboration needed for strengthening medical research in Europe 2Health News:Smokers Sleep Less Soundly 2Health News:Chemical chaperone could open door to treatment of neurological disorder 2Health News:Chemical chaperone could open door to treatment of neurological disorder 3Health News:Satellite data to deliver 'state-of-the-art' air quality information 2Health News:Keystone Human Services Acquires Impact Systems, Inc. 2
Straight shafts with 1 x 2 teeth. Serrated handle, non-magnetic and polished finish....
Straight shafts with pointed 4.5 mm tying surfaces. Scalloped wide handle with dull finish....
Straight shafts with 0.5 mm teeth and 6 mm tying platform. Wide serrated handle with thumb catch lock and polished finish....
Angled 45 degree shafts 8 mm long with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: